Navigation Links
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
Date:10/22/2013

t has been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown

Cardiovascular

  • An observational study showed an increase in MI with abacavir; a sponsor-conducted, pooled analysis did not show increased risk. In totality, the available data are inconclusive
  • The underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking)
  • Impaired Renal Function

  • Since EPZICOM is a fixed-dose tablet and the lamivudine component cannot be dose-adjusted, EPZICOM is not recommended for patients with creatinine-clearance <50 mL/min
  • Use With Other Abacavir-, Lamivudine- and/or Emtricitabine-Containing Products 

  • Do not use EPZICOM with other abacavir-, lamivudine- and/or emtricitabine-containing products
  • Adverse Events

  • In one study of therapy-naive patients (CNA30021), the most common adverse events (grade 2-4) reported with abacavir and lamivudine dosed once daily were hypersensitivity (9%), insomnia (7%), depression (7%), headache/migraine (7%), fatigue (6%), dizziness (6%), nausea (5%), diarrhea (5%), rash (5%), pyrexia (5%), abdominal pain (4%), abnormal dreams (4%), and anxiety (3%)
  • About ViiV HealthcareViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a 10% shareholder in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and ne
    '/>"/>

    SOURCE ViiV Healthcare
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Global Healthcare Leader Deploys QUOSAs Literature Management Tools
    2. Sysmex America Leads Educational Offerings Focused on Healthcare Reforms Impact on the Clinical Laboratory
    3. Hyland Software Partners with the Global Center for Healthcare Innovation in Cleveland
    4. Allied Healthcare Products Reports Loss On Sales Decline
    5. 50 Years Old and Still Bounding Over the Counter: Klines Healthcare Practice Continues to Deliver Unmatched OTC Market Intelligence
    6. Experian Healthcare launches tool to enable providers to identify and help enroll eligible individuals for health insurance exchange (HIX) subsidized programs
    7. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
    8. Orange County Hospital System, Integrated Healthcare Holdings, Joins ApolloMed ACO
    9. ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
    10. Hubble Telemedical Welcomes Healthcare Visionary Jonathan Lord, M.D. to Its Board of Directors
    11. Piramal
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
    (Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
    (Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
    Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
    ... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
    ... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
    Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
    (Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
    (Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of ... bamboo deckings . Moreover, the company has launched a ... available at deeply discounted rates. , As is ... the significance of online business nowadays. Thus, BambooIndustry.com pays ... workers are striving to deliver both value and efficiency ...
    (Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
    (Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
    (Date:10/19/2014)... Oct. 19, 2014 (HealthDay News) -- New stem cell-based ... lead to new treatments, a new study suggests. ... human intestinal tissue in a lab dish. They then ... for studying intestinal disorders, according to the researchers. ... diseases and conditions that can cause intestinal failure, from ...
    Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
    ... that the actress' current rehab spell will bring a stop ... incidents . ,As the Mean Girls star checked ... 28, after being arrested for DUI, her supposed friends got ... ,One friend told America's Star magazine that Lohan attempted to ...
    ... Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. ... and Drug Administration (FDA) for its Abbreviated ... Tablets, 12.5 mg and 25 mg. ,Mylan's ... June 29, 2007, concurrent with the expiration of ...
    ... the explosive growth of smoke-free air laws worldwide ... now protected by laws that require smoke-free air in ... momentum behind smoke-free air laws will continue accelerating because ... to protect the public from secondhand smoke. ...
    ... announced today the presentation of new analysis of data ... on the clinical development of their investigational drug, Viprinex(TM) ... the 16th annual European Stroke Congress in Glasgow, Scotland ... derived from the venom of the Malayan pit viper. ...
    ... our nation, Americans are very optimistic about the war ... nationwide survey sponsored by Abbott, nearly two-thirds (64%) believe ... ,"As an organization researching new options to ... will live up to the optimism expressed by Americans ...
    ... global public health community observes World No Tobacco Day, the ... epidemic that tobacco causes for our nation. Two important new ... can address the deadly toll of tobacco -- especially secondhand ... Tobacco Day. ,The Institute of Medicine, the group ...
    Cached Medicine News:Health News:Growth of Smoke-Free Air Laws Worldwide; More Than 200 Million Found "Fully Protected" 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:Americans Optimistic About the War on Cancer 2Health News:World No Tobacco Day Focuses on Secondhand Smoke 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: